KROS
Keros Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.32
+1.89%Aug 13, 2026, 07:33 UTC
Dimensional Fund Advisors LP increased its stake in Keros Therapeutics, Inc. by 453.9% during the quarter, acquiring an additional 263,347 shares, as disclosed in a Form 13F filing.
Source:Aug 3, 2026, 00:00 UTC
Keros Therapeutics reported a net loss of $28.7 million for Q2 2026, with zero revenue and diluted EPS of -$1.45, compared to a net loss of $30.7 million in Q2 2025.
Source:Jul 30, 2026, 20:01 UTC
Keros Therapeutics will receive a $20 million development milestone payment from Takeda after the first patient was dosed in the ELRiSE MDS clinical trial.
Source:Jun 25, 2026, 00:00 UTC
Keros Therapeutics appointed Anne Prener, M.D., Ph.D. as a Class III director of the Company.